Needham & Company Maintains a 'Hold' on Park Electrochemical (PKE);
Tweet
Share
E-mailGet Alerts PKE Hot Sheet
Price: $33.88 -0.06%
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Needham & Company maintains a 'Hold' on Park Electrochemical (NYSE: PKE).
Analyst, Sean K.F. Hannan, said, "PKE is facing a PCB demand environment that is partially subdued by the sluggish telecom/datacom spending (already well known). New products and eventual elimination of cost redundancies in the Advanced Composite business should aid the model in 2HF13 without a notable reliance on broader demand recovery, but at present we believe PKE remains growth-challenged."
"Our F1Q estimate becomes $45M & $0.21 (incl. opt.), vs. prior $51.3M & $0.37. F13 now $194M & $1.18, vs. prior $212M & $1.63. New F14 est. of $214M & $1.64."
For an analyst ratings summary and ratings history on Park Electrochemical click here. For more ratings news on Park Electrochemical click here.
Shares of Park Electrochemical closed at $26.05 yesterday.
Analyst, Sean K.F. Hannan, said, "PKE is facing a PCB demand environment that is partially subdued by the sluggish telecom/datacom spending (already well known). New products and eventual elimination of cost redundancies in the Advanced Composite business should aid the model in 2HF13 without a notable reliance on broader demand recovery, but at present we believe PKE remains growth-challenged."
"Our F1Q estimate becomes $45M & $0.21 (incl. opt.), vs. prior $51.3M & $0.37. F13 now $194M & $1.18, vs. prior $212M & $1.63. New F14 est. of $214M & $1.64."
For an analyst ratings summary and ratings history on Park Electrochemical click here. For more ratings news on Park Electrochemical click here.
Shares of Park Electrochemical closed at $26.05 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
- DA Davidson Starts Everus (ECG) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
